MA-BATTERY-VENTURES
Battery Ventures , a global, technology-focused investment firm, has closed new funds totaling $3.8 billion to continue backing innovative companies worldwide in a variety of sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005953/en/
The new funds—raised as Battery approaches 40 years of continuous operations—include Battery Ventures XIV and a companion fund, together capitalized at $3.3 billion, and the $530 million Battery Ventures Select Fund II, a vehicle intended to make additional investments primarily in portfolio companies of the firm’s other funds.
Battery will use the new capital to continue investing in companies at all stages, from seed and early-stage venture to buyout, in areas such as business software , including fin-tech and healthcare-IT; infrastructure software , including data/AI, developer tools and cybersecurity; consumer technology ; and industrial technology and life-science tools . The firm pursues a collaborative, research-driven style of investing and operates as one global team from offices in Boston, San Francisco, Menlo Park, New York, London and Tel Aviv.
Battery has invested in more than 450 companies globally since its inception, excluding seed-stage deals, resulting in 73 total IPOs and 195 M&A events*. Eight of the firm’s companies staged IPOs in 2021, and 13 had M&A exits. The portfolio companies that went public last year were Affirm, Amplitude, Braze, Coinbase, Confluent, Olo, Scodix and Sprinklr.
“Battery has successfully navigated up and down markets since its founding in 1983, and we remain extremely optimistic about the potential for disruptive new technology companies to be formed right now, despite—and even because of—the current market conditions,” said Michael Brown, a Battery general partner. “The fundamental trends driving the sectors we target, ranging from corporate digital transformation to remote work to open banking to the rise of online commerce, are stronger than ever. We’re excited to partner with talented founders and management teams; leverage our differentiated, stage-agnostic strategy; and invest these new funds in the next generation of technology companies.”
In conjunction with the new funds, Zack Smotherman has been promoted to general partner. He will continue to grow the firm’s efforts investing in the industrial-technology and life-science tools market. The industrial technology group has completed over 60 deals in the last 15 years, focusing on companies offering hardware, software and services for industrial and life science use cases, including critical test-and-measurement tools; workplace safety technology; and robotics, among other technologies.
In addition, Battery’s Shiran Shalev, based in Tel Aviv, was promoted to partner. Shalev joined Battery in 2013 and focuses on venture- and growth-stage investments in financial technology and business software.
Battery also recently hired veteran technology-sales executive Bill Binch as an operating partner and promoted several professionals in its growing portfolio-services and operations group. These include Karen Bommart, now investor-relations partner; Rebecca Buckman, marketing partner; Scott Goering, business-development partner; and Jenny Kang and Susanne Richman, now both talent partners. Additionally, Max Schireson—the former CEO of MongoDB who has been serving as a Battery executive-in-residence since 2015—was named operating partner.
“We’re excited to announce these well-deserved promotions on our investment team, which highlight our penchant for promoting homegrown talent, as well as our global footprint and ability to invest across stages and diverse sectors,” said General Partner Jesse Feldman. “On the services side, the promotions—as well as Bill’s and Max’s new roles—highlight our commitment to ramping up our expertise in areas like recruiting, leadership, culture, go-to-market services and marketing. We’re excited to offer our portfolio even more strategic and tactical help in those areas.”
Finally, the new pools of capital will allow Battery to continue expanding its focus on “majority-growth” investments, deals in which the firm takes majority-ownership stakes in growth companies, both bootstrapped and venture-backed. Battery has been backing such companies since 2008 and, since then, has completed majority-growth investments across 17 platform companies. Eight of those of those investments were made in the last three years.
Battery closed its thirteenth family of funds totaling $2 billion in February 2020 and announced Battery Ventures Select Fund I, capitalized at $400 million, a year later.
“I could not have asked for a better partner than Battery Ventures,” said Robbie Payne, the CEO of CAMBRIO, a manufacturing-software company acquired by Sandvik last year. “The team has always been experienced in, and extremely knowledgeable about, our market; well-networked; and always helpful in areas including strategy, recruiting, and sourcing acquisitions.”
Ara Mahdessian, co-founder and CEO of ServiceTitan, added: “ServiceTitan has been proud to partner with Battery Ventures for over six years. The firm’s incredible experience scaling B2B software companies has proven to be extremely impactful as we’ve grown to become the ‘Operating System of the Trades.’ The counsel Battery has provided us has been substantial. Many firms claim they’re more than just a monetary investment—and in my experience, Battery truly is.”
Finally, Cube Software Co-Founder and CEO Christina Ross said: “We knew finding a new venture partner in the current economic climate would be especially high stakes. In Battery, we found an experienced, well-networked investor who has seen this movie before—and we’re excited to start our journey with the firm in our corner.” Battery led a Series B investment in Cube, a financial-software company, last month.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London and Tel Aviv. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
*Data through March 31, 2022. Battery Ventures provides investment advisory services solely to privately offered funds. Battery Ventures neither solicits nor makes its services available to the public or other advisory clients. For more information about Battery Ventures’ potential financing capabilities for prospective portfolio companies, please refer to our website. For a complete list of portfolio companies, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005953/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom